key: cord-0701585-z0sezef8 authors: Kiziltan, Gamze; Tumer, Bilge Kagan Cetin; Guler, Onur Can; Ozaslan, Cihangir title: Effects of COVID‐19 pandemic in a breast unit: Is it possible to avoid delays in surgical treatment? date: 2021-11-02 journal: Int J Clin Pract DOI: 10.1111/ijcp.14995 sha: ab539397d36be5e60c8ce839e93792f9f4ee5c70 doc_id: 701585 cord_uid: z0sezef8 BACKGROUND: Coronavirus disease 2019 (COVID‐19) pandemic has caused fear all around the world. With people avoiding hospitals, there has been a significant decrease in outpatient clinics. In this study, we aimed to compare and explore the first peak of the pandemic period by studying its effects on patient applications, new diagnoses and treatment approaches in a non‐infected hospital. METHODS: We collected data from the first peak of the pandemic period in Turkey, from the pandemic declaration (11 March 2020) to social normalization (1 June 2020), and compared it with the data from a pre‐pandemic period with a similar length of time. We analyzed the data of breast cancer patients from application to surgery. RESULTS: The data of 34 577 patients were analyzed for this study. The number of patients who applied to outpatient clinics decreased significantly during the pandemic period. After excluding control patients and benign disorders, a figure was reached for the number of patients who had a new diagnosis of breast cancer (146 vs. 250), were referred to neoadjuvant treatment (18 vs. 34), and were treated with surgery (121 vs. 229). All numbers decreased during the pandemic period, except for surgeries after neoadjuvant treatment (21 vs. 25). Surgical treatment approaches also changed. However, the rate of newly diagnosed breast cancer patients treated with surgery was similar in both periods. None of these patients were diagnosed with COVID‐19 or died during the pandemic. CONCLUSION: This study shows that non‐infected hospitals can be useful in avoiding delays in the surgical treatment of cancer patients. This single-centre, retrospective, observational cohort study includes patients admitted and treated in the breast unit of the University of Health Sciences Ankara Oncology Hospital between 21 December 2019 and, 1 June 2020. Data were collected from the hospital database. The WHO declared the COVID-19 pandemic on 11 March 2020. 5 According to the Turkish Ministry of Health statistics, a rapid increase of infected patients was seen in the first month of the pandemic; however, the situation stabilized in June 2020. 6 Between 11 March and 1 June 2020, most of the population was advised to stay at home. Since 1 June, our country has seen the onset of social normalization. In Turkey, hospitals were classified into three groups: pandemic hospitals, non-infected hospitals that do not admit patients with proven COVID-19, and combined hospitals admitting COVID-19 patients and others. Our hospital was in the second group. We continued both emergency surgeries and malignancy procedures but did not admit patients with either suspected or proven COVID-19. In this study, patients were explored in two groups. The first group was from the pandemic period, ie, 11 March 2020, to 1 June 2020. The second group was from a similar period (82 days) before the pandemic. For these two groups, patients who applied to our outpatient clinics were analyzed. After excluding other medical conditions, 11 479 patients were analyzed to explore diagnoses and treatment approaches for breast disorders. Control patients and benign breast disorders were excluded to analyze breast cancer patients particularly. An outpatient clinic for patients suspected of being infected with Sars-CoV-2 was established in the hospital garden. In this way, neither suspected nor infected patients entered the hospital. The emergency room entrance was also separate. Patients were given a temperature check at all of the hospital entrances and those with fever were referred to the separate outpatient clinic mentioned above. There was a separate inpatient clinic and intensive care unit for isolating suspected patients who already had surgery. All patients were given a PCR test for Sars-CoV-2 before hospitalization during pre-operative preparations, to hospitalize only negative patients. PCR tests were repeated to avoid new contaminations and false negativity in delays of more than two days before surgery. We made diagnoses and perform staging, preoperative preparations and treatment decisions permanently in outpatient clinics. We did not hospitalize patients before their operations without necessary situations. We also shorten hospitalization time and discharged patients immediately after surgery unless any complications occurred. Before discharging patients, we educated them about postoperative wound care, possible risks or complications, and protection from Sars-CoV-2 infection. Postoperative follow-ups were made by phone calls and applications to outpatient clinics after discharge. We did not operate on patients who had benign diagnoses without suspected malignancy or non-emergency cases during the pandemic period. The number of surgeries was limited for each operating room to reduce personnel exposure and limit the risk of spreading infection. The distribution of the variables analyzed using visual (histogram and probability graphs) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). Definitive analyzes were performed as frequency tables for categorical variables. Median and range were calculated for the continuous variable (age). The numbers for admissions, breast cancer diagnoses, operation types and pathological results of each group were compared. Differences between the groups in terms of these frequencies were compared using the Pearson chi-Square test. P values <0.05 were considered statistically significant. The COVID-19 pandemic has caused fear worldwide. Curfews, social distancing and hospital avoidance have reduced routine controls and screening programs. Some new algorithms were published for breast cancer treatment throughout the pandemic, which were suggested postponing surgical treatment for low-risk patients because of the increased infection risk in hospitals. However, we have seen postponing cannot be a solution. The effects of the Sars-CoV-2 pandemic and its spread continue to be seen. Another way has to be found to treat cancer patients but postpone surgical treatment or risk their lives in hospitals. Non-infected hospitals may be the answer to this issue. All analyses were performed with SPSS software (Statistical Package for the Social Sciences, version 25.0; SPSS Inc, Chicago, IL, USA). We explored a total of 34 577 patients who applied to outpatient clinics in our hospital. With the declaration of the pandemic, the number of applications to our outpatient clinics noticeably decreased ( Figure 1 ). After excluding other medical conditions, there were 11 479 patients with breast disorders. There were 2420 patients who had breast cancer in our outpatient clinics (Table 1) . Two hundred and fifty patients had a breast cancer diagnosis before the pandemic (Group 2) and 146 during the pandemic period Similarly, the increase in the positivity rate of sentinel lymph node biopsies in the pandemic period was not statistically noticeable (P = .76). There were 19 patients (30.1%) who had metastatic sentinel lymph nodes in group 1 and 31 patients (28.4%) in group 2 ( Table 2) . Patients had larger tumours and more lymph node metastases in the pandemic period (Table 3 ). There was a statistically significant difference between the two groups for tumour size. When we compared two groups for t0 and t1 tumours with bigger ones (t2-3-4), we found more big tumours in the first group (P = .01). On the contrary, there was no significant difference in lymph node positivity rates (P = .22). But we found a statistically significant difference between the two groups for stages. More early-stage breast cancer (stages 0-1-2a) patients in the second group (P = .02). Further, there were more DCIS (ductal carcinoma in-situ) patients but no significant changes in the pathological type of tumours (P = .30). There were 12 benign operations during the pandemic period. Indications for these operations were biopsies to diagnose granulomatous mastitis, abscess, phyllodes tumours and growing masses suspected of malignancy. We had no COVID-19 positive patients during this period. (Table 3) . Increased stages may be related to people waited longer to be seen during the pandemic because of their fear of going to a hospital. Or more severe cases applied to hospitals than patients with asymptomatic tumours. Furthermore, the rate of surgeries after neoadjuvant treatment was higher in the second group. As a result, there was a slightly increased mastectomy rate and a significant increase in stages. The number of breast cancer operations after neoadjuvant treatment did not change because their treatments had already been planned. Also, the rate of patients referred to neoadjuvant therapy was similar in both groups. There are limitations to our study. We need more data covering a longer period of time to consider the pandemic's effect on the stages of cancer. This retrospective single-centre observational study does not lend sufficient statistical power to draw firm conclusions. The hospital in which we were working was a non-infected hospital, so we could continue with malignant surgeries under the new rules mentioned before. Working in a non-infected hospital allowed us to continue surgical oncology procedures more securely without compromising scientific suggestions in guidelines for cancer patients. There were no significant differences in our treatment approach for breast cancer patients in our hospital and no extra delays for surgery. The effects of the Sars-CoV-2 pandemic and its spread continue to be seen. Another way has to be found for the treatment of cancer patients but postponing surgical treatment. Non-infected hospitals may be the answer to this issue. A part of this study was contributed as a poster at the 12th European Breast Cancer Conference (https://regis ter.event -works.com/elsev ier/ebcc2 020/ps/pd/id/83067/). The authors declare that they have no conflict of interest. Study concept and design: Cihangir Ozaslan and Gamze Kiziltan. Cihangir Ozaslan and Gamze Kiziltan. The data were collected retrospectively and approved by our institutional ethics committee. Also, we obtained permission for this study from the Turkish Ministry of Health Scientific Research Commission (Approval Code: 2020-07.10T00_25_31) and Institutional Review Board (Approval Code: 2020-08-04-99). The data that support the findings of this study are available on request from the corresponding author. The data are not publicly avail- Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic Breast cancer diagnosis, treatment and follow-up during COVID-19 pandemic [published correction appears in Eur J Breast Health Cancer surgery scheduling during and after the COVID-19 first wave: the MD Anderson Cancer Center Experience Maintaining breast cancer care in the face of COVID-19 Timeline of WHO's response to COVID-19 COVID-19 situation report Turkey Changes in breast cancer management during the Corona Virus Disease 19 pandemic: an international survey